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Abstract  
The European Neuroendocrine Tumor Society (ENETS) proposed standard of care 
guidelines for Pathology in 2009. Since then, profound changes in the classification 
have been made, with the separation of neuroendocrine neoplasia (NEN) into well 
differentiated neuroendocrine tumours (NET) and poorly differentiated 
neuroendocrine carcinomas (NEC) in the 2010 WHO classification. The 7th edition of 
the TNM classification (2009) included NEN for the first time, adapting widely ENETS 
proposals but with some differences for NEC and for NET of the pancreas and the 
appendix. Therapy guidelines for gastro-entero-pancreatic NET have been updated 
2016. The need for update of the standards of care prompted ENETS to organize a 
consensus conference which was held in Antibes in 2015; a working group was 
designated to propose pathological standards of care.  
 
Introduction 
The European Neuroendocrine Tumor Society (ENETS) proposed standard of care 
guidelines for Pathology in 2009 [1]. Since then, profound changes in the 
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(NEN) into well differentiated neuroendocrine tumours (NET) and poorly 
differentiated neuroendocrine carcinomas (NEC) in the 2010 WHO classification [2]. 
The 7th edition of the TNM classification (2009) included NEN for the first time, 
adapting widely ENETS proposals but with some differences for NEC and for NET of 
the pancreas and the appendix [3]. Therapy guidelines for gastro-entero-pancreatic 
NET have recently been updated as well [4]. The need for update of the standards of 
care prompted ENETS to organize a consensus conference which was held in 
Antibes in 2015; a working group was designated to propose pathological standards 
of care.  
 
Gross analysis and processing of tissues 
Histopathological analysis of tissue specimens is the gold standard for the diagnosis 
of NEN. Conventional morphological analysis is completed by immunohistochemistry, 
required to demonstrate the neuroendocrine phenotype and to evaluate Ki67 index. 
Samples can be obtained by endoscopy, but mini-biopsy is preferred to the classical 
fine needle aspiration with smears only [5, 6]. Tissue specimens are gained by 
biopsy of a primary or secondary tumor, by surgical resection or by endoscopic 
resection. Tissues are fixed in formalin and embedded in paraffin. Resection 
specimens require a detailed gross examination to select the proper regions for 
histological analysis. Gross examination is also crucial to provide data for T- and N- 
staging and to select the regions to analyze for establishing resection status. 
 
Diagnostic Standards:  
Neuroendocrine phenotype: 
Table 1 summarizes the mandated and optional immunohistochemical requirements 
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neuroendocrine phenotype is suspected, immunohistochemical stainings for 
synaptophysin and chromogranin-A are required to definitely confirm this hypothesis 
[7]. Cytokeratin staining might be useful to confirm the epithelial nature of the tumor 
and to rule out paraganglioma. In well differentiated NET, all tumor cells stain 
diffusely for synaptophysin because of the diffuse presence of small clear vesicles. 
The expression of chromogranin A is usually more heterogeneous in the cytoplasm 
of tumor cells, since it depends on the presence of large neurosecretory granules. 
Rectal NET may frequently stain negative for chromogranin A with most monoclonal 
antibodies of current use. Otherwise, care must be taken in diagnosing well 
differentiated NET without any chromogranin-A expression; other entities, such as 
solid pseudopapillary neoplasia of the pancreas, acinar cell carcinoma or 
adrenocortical neoplasms must be ruled out. In poorly differentiated NEC, however, 
chromogranin-A may be lacking: moreover, in some small cell NEC, synaptophysin 
also may be focal or absent: in such tumors, the diagnosis of “small cell 
neuroendocrine carcinoma” is a diagnosis of exclusion. The use of other so-called 
neuroendocrine markers such as neuron-specific enolase (NSE) or N-CAM (CD56) is 
discouraged due to their low specificity [8].  
Differentiation 
According to the WHO classification, NEN are separated into well differentiated NET 
and poorly differentiated NEC. Initially, the assumption was that all G1-G2 tumors 
were well-differentiated and all G3 tumors were poorly differentiated. However well 
differentiated NET can rarely have proliferation indexes >20% especially in the 
pancreas. These patients survive longer than patients with poorly differentiated NEC 
[9], but shorter than patients with well differentiated NET. This new entity has by 
some been classified as well differentiated NET G3 [10]. These well differentiated 
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vessels, organoid growth pattern without expansile growth and absence of 
geographic necrosis or desmoplastic stroma. Well differentiated morphology 
correlates with Ki67 index range of 20% to 50% [9-12]. Therefore, the exact Ki67 
index as well as differentiation needs to be included into pathology reports. For NEC, 
small cell and large cell morphology should be described. 
Grading: 
Once the neuroendocrine nature of a tumor is demonstrated, the proliferative activity 
has to be assessed using Ki67 staining and performing a staining index. The 
percentage of positive tumor nuclei has to be assessed and reported. Grading is 
performed as defined in WHO and UICC/AJCC classifications (See Table 2). Ki67 
index seems to be more accurate and reproducible than mitotic count [13] [14] and is 
the only counting possible on biopsy samples. Therefore, Ki67 index is regarded as 
compulsory and mitotic count optional. Grading can be performed as well on primary 
tumors as on metastases, but some heterogeneity exists between both and between 
different metastases [15, 16] [17]; the proliferation index is often higher in 
metastases. If not enough material for hotspot selection and analysis of 2000 tumor 
cells is available, undergrading might occur [18], this is occurring in EUS-obtained 
mini-biopsies [5, 19]. Grading is not recommended on smears from fine needle 
aspiration, but reliability is increasing in mini-biopsies, also gained by endoscopic 
procedures [6]. The risk of undergrading decreases between 200 and 2000 cells 
examined [19, 20] and was minimal when > 2000 cells were counted [20]. Finally, the 
amount of tissue needed depends on the purpose of the analysis. Only a limited 
number of cells is enough for discriminating well differentiated NET G1/G2 from 
poorly differentiated NEC G3 but might be not sufficient for an accurate grading. 
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The use of optional or additional markers including hormones or transcription factors 
may be employed in the setting of a neuroendocrine tumor metastases of unknown 
primary site: Serotonin and cdx-2 positivity are in favor of a primary of the small 
intestine, islet-1 (Isl-1) expression is found in primaries of the pancreas and 
duodenum and TTF1 in primaries of the lung and in medullary thyroid carcinoma [21], 
the second together with calcitonin. All these markers are of no use in the setting of 
poorly differentiated NEC [22].  
Immunohistochemical detection of somatostatin receptors (SSTR), especially 
SSTR2, is feasible and indicated in the absence of in-vivo somatostatin imaging 
studies [23, 24]. In the case of questionable vascular invasion, immunohistochemistry 
for endothelial cell markers such as CD34 or special stains for the visualization of 
vessel walls might be of help. 
Pathological report 
Table 3 summarizes the minimum requirements for pathological reports of resection 
specimens or biopsy specimens of NEN. 
 
Needs for research 
MGMT expression or methylation may serve as a predictive marker of response to 
temozolomide based chemotherapy in PanNET: clinical trials are on the way to 
address this issue. In the same regard, translational studies are needed to define 
biomarkers predicting response to other therapies such as targeted therapies or 
other chemotherapeutic strategies. The new category of NET G3 needs to be better 
defined pathologically, possibly by the inclusion of molecular markers in order to 
have a more solid basis to define the therapeutic consequences of this tumor type. At 
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mutational, expression or methylation profiles, but so far no therapeutic strategies are 
based on these findings.  
 
Conclusions 
The proposed standard procedures for diagnosing NEN should now follow the WHO 
and TNM classification systems that are under revision. A standardized diagnosis is 
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Table 1. Mandatory and optional elements for assessing a biopsy specimen 
containing a tumor with features of a GEP-NEN 
Mandatory 
Morphology and differentiation on HE section 
Immunostaining for neuroendocrine markers 
– Synaptophysin and chromogranin A 
Immunostaining for proliferation marker 
– Ki67/MIB1  
Optional 
Immunostaining for hormones such as insulin, gastrin, serotonin and others 
– In the context of hormonal symptoms, liver metastases of an unknown primary 
or follow-up of a tumor with a hormonal syndrome 
Immunostaining for transcription factors (TTF1, CDX2, Isl-1) 
– In the context of a carcinoma of unknown primary 
Immunostaining for somatostatin receptor (i.e. SSTR2)  
– If not available by in-vivo technique such as SRS imaging  
Immunostaining for vessel markers  





Table 2. Grading of GEP-NENs: 
Grade  Mitotic count, 10 HPF1 Ki67 index, %2 
G1 <2 <33 
G2 2-20 3-20 
G3 >20 >20 
 
1 HPF = high-power field = 2 cm2, at least 40 fields evaluated in areas at highest 
mitotic density. 
2 MIB1 antibody; % of 500 to 2,000 cells in areas of highest nuclear labeling. If less 
cells, the number of assessed cells should be noted. 
3 <3 could replace ≤2 in the 2010 WHO classification in order to include decimal 
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Table 3. Minimum requirements of pathology reports, given for the example of 
pancreatic NET, according to CAP guidelines 
Type of specimen: Excisional biopsy, parial pancreatectomy, Whipple 
resection, total pancreatectomy 
Tumor site: pancreatic head, body, tail, uncinated process. 
 
Tumor size: in cm and 3 dimensions 
Tumor focality: unifocal, multifocal 
Tumor functionality Insulinoma, Glucagonoma, Somatostatinoma, 




well differentiated, poorly differentiated* 
 
Proliferation rate: Ki-67 index + optionally mitotic count 
Tumor necrosis: present, absent 
Microscopic tumor 
extension 
confined to pancreas, invading peripancreatic soft tissue, 
invading other organs 
Margins: margins uninvolved by tumor, closest margin in cm, 





Perineural invasion: present, absent 
TNM staging (UICC 7th 
edition): 
 
Lymphnodes: number of lymphnodes examined, number of 
lymphnodes involved 
Additional features  
* note that for poorly differentiated NEC the TNM system of adenocarcinomas of the 
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